
Claims


1. Use of (1) a (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide represented by the following formula 1 or a pharmaceutically acceptable salt thereof; and (2) a sorafenib represented by the following formula 2 or a pharmaceutically acceptable salt thereof:

Formula 1



;

Formula 2



in the manufacture of a medicament for the treatment of liver cancer.

2. The use of claim 1, wherein the pharmaceutically acceptable salt of sorafenib is a p-toluenesulfonate salt.

3. The use of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt thereof is to be administered parenterally or orally.

4. The use of claim 1, wherein the sorafenib or the pharmaceutically acceptable salt thereof is to be administered orally.

5. The use of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt is to be administered 1 to 5 times per week.

6. The use of claim 1, wherein the sorafenib or the pharmaceutically acceptable salt

thereof is to be administered 1 to 7 times per week.

7. The use of claim 6, wherein the sorafenib or the pharmaceutically acceptable salt thereof is to be administered once or twice per day.

8. The use of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt is to be administered 1 to 5 times per week, and the sorafenib or the pharmaceutically acceptable salt thereof is to be administered 1 to 7 times per week.


9. The use of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt thereof is to be administered parenterally once per week on day 1 of each week, and the sorafenib or the pharmaceutically acceptable salt thereof is to be administered once per day during day 1 to day 6 of each week.

10. The use of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt thereof is to be administered orally once per day on days 1, 3 and 5 of each week (three times per week), and the sorafenib or the pharmaceutically acceptable salt thereof is to be administered once per day (7 times per week).

11. The use of claim 4, wherein the sorafenib or the pharmaceutically acceptable salt thereof is to be administered at 20 minutes to 1 hour after oral administration of the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt thereof.

12. Use of a (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide represented by the following formula 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of liver cancer:


Formula 1



,

wherein the medicament is to be co-administrated with sorafenib represented by the following formula 2 or a pharmaceutically acceptable salt thereof:

Formula 2



.